Vimta Labs Limited (BOM:524394)
India
· Delayed Price · Currency is INR | Market Cap | 20.11B |
| Revenue (ttm) | 3.94B |
| Net Income (ttm) | 741.31M |
| Shares Out | 44.67M |
| EPS (ttm) | 16.49 |
| PE Ratio | 27.10 |
| Forward PE | n/a |
| Dividend | 1.00 (0.22%) |
| Ex-Dividend Date | May 30, 2025 |
| Volume | 5,855 |
| Average Volume | 9,537 |
| Open | 455.05 |
| Previous Close | 453.20 |
| Day's Range | 449.10 - 462.90 |
| 52-Week Range | 377.30 - 902.85 |
| Beta | -0.28 |
| RSI | 49.03 |
| Earnings Date | May 6, 2026 |
About Vimta Labs
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufactu... [Read more]
Financial Performance
In fiscal year 2025, Vimta Labs's revenue was 3.45 billion, an increase of 19.25% compared to the previous year's 2.90 billion. Earnings were 667.55 million, an increase of 36.76%.
Financial StatementsNews
Vimta Labs Ltd (BOM:524394) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Vimta Labs Ltd (BOM:524394) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
Q3 2026 Vimta Labs Ltd Earnings Call Transcript
Q3 2026 Vimta Labs Ltd Earnings Call Transcript
Vimta Labs Transcript: Q3 25/26
Q3 FY26 revenue grew 10.2% year-over-year, led by pharma and food testing, though operational delays deferred some revenue. Nine-month EBITDA margin was 35.1%, with exports rising to 39% of income. Biologics services launch in Q1 FY27, and Q4 is expected to be seasonally strong.
Vimta Labs Ltd (BOM:524394) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic ...
Vimta Labs Ltd (BOM:524394) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Expansions Propel Growth
Q2 2026 Vimta Labs Ltd Earnings Call Transcript
Q2 2026 Vimta Labs Ltd Earnings Call Transcript
Vimta Labs Transcript: Q2 25/26
Record Q2 FY26 revenue and profit growth were driven by pharma and food testing, with strong margins and a net debt-free position. Capacity expansions and CapEx support future growth, especially in biologics, while both domestic and export markets contribute to momentum.
Vimta Labs shares hit fresh all-time high, surges 7%
Vimta Labs, a small-cap player in the healthcare services sector, witnessed a strong rally in Friday’s session, jumping 7.18% to hit a new 52-week high of ₹856.40. The stock registered an intraday inc...
Vimta Labs shares surge 7%, hit fresh 52-week high amid heavy trading volumes
Vimta Labs shares soared 7% in early trade today, reaching a new 52-week high of ₹828.90 amid robust market activity. The stock opened at ₹792.10 and gained steadily from the previous close of ₹763.90...
Vimta Labs Transcript: Q1 25/26
Q1 FY26 saw record revenue of INR 993 million, up 31.4% year-on-year, with strong EBITDA margin of 35.7% and profit after tax up 35.9%. Growth was broad-based across pharma, food, and electronics testing, with robust export gains and a 1:1 bonus issue approved.
Stocks to watch on April 29: Wipro, UCO Bank, Central Bank of India, Go Digit, Avenue Supermarts, Oberoi Realty, Ultratech, Vimta Labs, RBL Bank
The Indian stock market is likely to react to a host of corporate earnings, operational updates, and sector developments on Monday, April 29. Companies such as UCO Bank, Central Bank of India, Go Digi...
Vimta Labs Q4 FY25 profit rises 31% YoY; announces 1:1 bonus issue and new biologics R&D foray
Vimta Labs Limited reported robust financial results for the fourth quarter and financial year ended March 31, 2025, backed by strong growth in its pharmaceutical services business. Financial highligh...
Vimta Labs Transcript: Q4 24/25
Revenue grew 19.1% year-over-year in FY2025, led by pharma services and strong export growth. Margins improved, CapEx guidance is INR 900 million for FY2026, and a major expansion into biologics CDMO is underway. Repeat business remains above 90%.
Vimta Labs shares surge 34% in past one month
Vimta Labs has been a standout performer in the stock market, with its shares surging 34% over the past month. The stock hit a 52-week high of ₹980.75 on December 6, 2024, reflecting strong investor i...
Vimta Labs Transcript: Q2 24/25
Q2 FY25 saw 26.4% YoY revenue growth, driven by pharma services and improved margins post-diagnostics divestment. The company targets a 500 crore run rate in FY26, with sustainable mid-30% EBITDA margins and ongoing capacity expansion.
Vimta Labs Transcript: Q1 24/25
Q1 FY25 saw stable performance with 3% sequential revenue growth, strong margins, and continued capacity constraints. New Hyderabad facility and CapEx are set to drive growth, with management targeting INR 500 crore revenue by FY26.